2025 Annual Meeting | Industry Therapeutic Update from Annexon Biosciences: Advancing GBS Care: Latest Insights into the role of classical complement pathway in GBS

Date Tuesday 04/08/25

Time 06:00 PM - 08:00 PM PDT Add To Calendar

Location Marriott Marquis | San Diego B

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Jeffrey C. Allen, MD, FAAN, Nicholas J. Silvestri, MD, FAAN, Avni Kapadia, MD

Topic(s) General Neurology

Learning Objectives Stay up to date on new advances in GBS and review emerging data and contemporary controversies. Data from the clinical development program of the novel C1q inhibitor ANX005 will also be reviewed, followed by time for Q&A.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
06:00 PM - 08:00 PM PDT	Speaker	Industry Therapeutic Update from Annexon Biosciences: Advancing GBS Care: Latest Insights into the role of classical complement pathway in GBS

Faculty Disclosures
Jeffrey C. Allen, MD, FAAN	No disclosure on file
Nicholas J. Silvestri, MD, FAAN	Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for argenx. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for argenx. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. The institution of an immediate family member of Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB. Dr. Silvestri has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Silvestri has received publishing royalties from a publication relating to health care.
Avni Kapadia, MD	Dr. Kapadia has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Annexon. The institution of Dr. Kapadia has received personal compensation in the range of $0-$499 for serving as a Consultant for Re Cognition. Dr. Kapadia has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Robbins Travis.

��ɫ��

��ɫ��